# Integrating ID in OUD Care: A Tale of Two Settings

Sarah Kattakuzhy, Aaron Greenblatt, David Sternberg, Elana Rosenthal



#### **Disclosure Information**

#### Sarah Kattakuzhy, MD

 Principal investigator on investigator-initiated grant with Gilead Sciences, paid to the institution

#### ♦ Aaron Greenblatt, MD

- No Disclosures
- ♦ David Sternberg, MHA
  - No Disclosures
- Elana Rosenthal, MD

 Principal investigator on investigator-initiated grant with Gilead Sciences, Merck, and the John Martin Foundation, paid to the institution



### **Learning Objectives**

To review the evidence-base around integration of infectious disease and opioid use disorder care

 To understand real-world perspectives of care integration across the treatment landscape, from harm reduction to traditional OTP settings

To discuss barriers and facilitators to care integration across a variety of practice settings



# Evidence Base on Integration of ID and OUD Care



## MOUD Reduces HIV and HCV Incidence

HCV Incidence in Young PWID



Tsui, JAMA IM 2014

#### Engagement in MOUD Improves HIV Outcomes



A CAM WE CALL

Altice, JAIDS 2011

#### MOUD Associated with Higher Rates of HCV Cure in PWID





Rosenthal, CID 2020

#### Addiction Consultation for Patients Hospitalized with Infections from OUD



Increased treatment for OUD

 Greater likelihood of completing antibiotics

 Decreased likelihood of patients leaving AMA





#### Collocation of HIV and MOUD Increases MOUD Uptake and Improves OUD Outcomes



93 HIV infected patients with OUD
Randomized to:
Collocated buprenorphine
Case-management and referral to OTP

- Collocated buprenorphine
   Improved uptake of MOUD (74% vs 41%)
  - Fewer opiate positive urine drug screens
  - Improved HIV primary care visit adherence

#### Improved HCV Visit Attendance with Collocated MOUD



### **Collaborative Care vs Collocated Care**



 IMPACT study 18 PCP clinics from 8 health care organizations in 5 states

1801 patients >/=60 with depression
 Randomized to:

 -Usual care
 -IMPACT intervention

45% of intervention patients had a reduction in depressive symptoms from baseline compared with 19% of usual care participants



Unützer J, JAMA 2002

# Barriers to Integration of OUD and ID Treatment



## **Challenges of OUD Care**

Regulations of OUD treatment
Limited treatment facilities
Limited providers
Prior authorization





Parks, J Addiction Medicine 2019 Jones, AJPH 2015

### **Payment and Financing Limitations**

 Services helpful to patients seeking integrated care for OUD and ID are difficult to obtain or sustain financially

Same-day billing restrictions

As of 2019, 13 states do not allow providers to bill for a physical and a behavioral health visits in the same day



## Lack of Data Integration and Sharing

#### ♦42 CFR Part 2

Prescription medication interaction
 Prescriptions of medications with significant risk of abuse/diversion/misuse in patients on MOUD

- Social determinants of health affecting treatment success
- Screening/immunization for conditions related to OUD





Walley, JGIM 2009

#### **Limits on Harm-Reduction Services**



< 400 SSP in the US • Federal ban lifted in 2016 Ongoing barriers Federal funding does not cover injection equipment Must be in a region with or at risk of increase in HIV and viral hepatitis

#### **Stigma Discrimination**







Disregard for the disease model of addiction Misconceptions about OAT Criminalization of substance use disorder

"Replacing one addiction with another"



**Case Studies:** Integration of ID and OUD **Care in Baltimore and** Washington DC



## **Rising Rates of Infections in PWID**



Lyss, JID 2020

#### Restrictions on HCV Medications: <u>Medicaid</u>





Barua, Ann Intern Med. 2015

### HARP: Baltimore, Maryland



### HIPS: Washington, DC









### The Rules Are Always Changing!

#### Payers, Regulations, Local Rules will look different

- ♦ Between sites
- ♦ Over time







#ASAM2021



#### **Practice Implementation**





#### **Patients and Personnel**





#ASAM2021





#### Reliability

Longevity of Partnership

**Continuity of Presence** 

Quality of Care



#ASAM2021

#### Staffing

#### Community Health Worker

#### Dedicated Medical Assistant







#### **Care Coordination**



#### HIV/HCV Testing



Syringe Exchange and Naloxone Distribution



#### Intake Protocol





#ASAM2021

# **Unique Challenges**



### **Breakout Groups**



#### **Breakout Group Format**

♦You are a provider at one of four practice settings:

- A syringe exchange program
- ♦ a primary care clinic
- ♦ a buprenorphine telemedicine clinic
- An opioid treatment program

 Moderator will guide a discussion on barriers and facilitators of integrated care specific to your setting



## Discussion







#### **Summary**

There is strong evidence base to support care integration across disciplines

There are unique challenges based on type of care integration, practice setting, and region

Billing and practice implementation challenges can be overcome with time and planning

Patient and practice integration challenges can be improved with high-quality, culturally competent care

Staffing is critical

Care integration is practical, patient-centered, and the future!

#### References

- Tsui, JAMA IM 2014
- Altice, JAIDS 2011
- Rosenthal, CID 2020
- Marks, CID 2018
- Lucas, Annals 2010
- Rosenthal, ID Week 2019
- Unützer J, JAMA 2002
- <u>www.pewtrusts.org</u>
- Opioid.amfar.org
- Parks, J Addiction Medicine 2019
- Jones, AJPH 2015
- Barua, Ann Intern Med 2015
- Peters, N Engl J Med 2016

